High-Dose vs. Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial
Skaarup KG. et al, (2025), Circulation: heart failure
Risk of Myocarditis or Pericarditis with High-Dose versus Standard-Dose Influenza Vaccine: A Prespecified Analysis of the Randomized DANFLU-2 Trial
Landray M. et al, (2025), Jama network open
Recommended methodologies for clinical investigations of high-risk medical devices – Conclusions from the European Union CORE–MD Project
Landray M. et al, (2025), The lancet regional health. europe
High-dose versus standard-dose inactivated influenza vaccine and cardiovascular risk: the DANFLU-2 trial
Landray M. et al, (2025), European heart journal
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial
Zhou J. et al, (2025), Eclinicalmedicine
Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
Horby PW. et al, (2025), Lancet infectious diseases
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
Horby P. et al, (2025), Lancet infectious diseases
Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression
Greene T. et al, (2025), Clinical journal of the american society of nephrology, 20, 632 - 641
Correction: Large simple randomized controlled trials-from drugs to medical devices: lessons from recent experience.
Buccheri S. et al, (2025), Trials, 26
Large simple randomized controlled trials-from drugs to medical devices: lessons from recent experience.
Buccheri S. et al, (2025), Trials, 26
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Judge P. et al, (2024), Nephrology dialysis transplantation
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol dial transplant
Accelerating Evidence Generation: Addressing Critical Challenges and Charting a Path Forward
Landray M., (2024), Journal of clinical and translational science
Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: a post-hoc analysis of the DANFLU-1 randomized clinical trial
Christensen J. et al, (2024), Journal of infection
Overcoming the barriers to better evidence generation from clinical trials
Landray M., (2024), Trials
In practice: RECOVERY Trial
Horby P. et al, (2024), Principles and Practice of Emergency Research Response, 345 - 350